5 terminated. 5 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Terminated 5 |
| Phase 2 | 3 | Terminated 3 |
Follow Muscle Hypertonia: new trials by email Literature Review of Muscle Hypertonia trials Research Report on Muscle Hypertonia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Intramuscular Injections of ABBV-950 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Upper Limb Spasticity ABBV-950, BOTOX, Placebo for ABBV-950 - Upper Limb Spasticity | Phase 1 | Terminated | AbbVie | 1 | 2024-01-12 | 2024-07-01 |
| One Year Extension Study To Protocol C2/5/TZ:MS-05 sublingual tizanidine 12 mg - Spasticity, Multiple Sclerosis | Phase 1 / Phase 2 | Terminated | Teva GTC | 10 | 2008-01-01 | 2009-02-19 |
| Botox vs. Baclofen for Upper Limb Spasticity intramuscular Botox versus oral baclofen - Spasticity | Phase 1 | Terminated | Vanderbilt University | 8 | 2006-02-01 | 2012-01-20 |
| Cannabis for Spasticity in Multiple Sclerosis Inhaled Cannabis, Oral THC, Oral Placebo - Multiple Sclerosis | Phase 1 / Phase 2 | Terminated | University of California, Davis | 41 | 2004-04-14 | 2018-05-18 |
| Cannabis for Spasticity in Multiple Sclerosis Smoked Cannabis - Multiple Sclerosis | Phase 1 / Phase 2 | Terminated | Center for Medicinal Cannabis Research | 60 | 2003-03-01 | 2007-04-04 |
Muscle Spasticity (5) · Multiple Sclerosis (3) · Marijuana Abuse (2) · Fatigue (1) · Stroke (1)
Muscular Diseases (5) · Musculoskeletal Diseases (5) · Nervous System Diseases (5) · Neurologic Manifestations (5) · Neuromuscular Manifestations (5) · Pathological Conditions, Signs and Symptoms (5) · Signs and Symptoms (5) · Autoimmune Diseases (3) · Autoimmune Diseases of the Nervous System (3) · Demyelinating Autoimmune Diseases, CNS (3) · Demyelinating Diseases (3) · Immune System Diseases (3) · Chemically-Induced Disorders (2) · Mental Disorders (2)
Botulinum Toxins, Type A (1) · Dronabinol (1) · nabiximols (1)
AbbVie (1) · Center for Medicinal Cannabis Research (1) · Teva GTC (1) · University of California, Davis (1) · Vanderbilt University (1)
United States (4) · Israel (1)
Arnon Karni, MD (1) · Mark Agius, M.D. (1) · Michelle Apperson, MD, PhD (1) · P. David Charles, MD (1)